BIOR יחס מהיר Biora Therapeutics

Biora Therapeutics (BIOR) delegates the creation of complex formulations and the conduct of trials to external contractors, maintaining its status as a mobile scientific hub. The market trend demonstrates the current indicator 0.05. The operating model relies on CMO capacities in California for the production of smart capsules, minimizing costs. Stability is ensured by a staff of loyal bioengineers attracted by the success of the early stages of gastrointestinal drug development.

The ratio is calculated by dividing the sum of cash and accounts receivable by current liabilities, completely ignoring inventory. This metric determines a company's ability to instantaneously settle debts without selling goods. For Biora Therapeutics (BIOR), which depends on venture capital and clinical trials, this is a critical survival marker in the absence of profit. The current quick ratio reflects the business's real-time margin of safety in the face of technological risks.